Importantly, our results obtained from CML xenograft mouse model further demonstrate the in vivo efficacy of propofol and its synergistic effects with BCR-ABL TKIs (Fig. 4). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.